{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-025657","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.910187+00:00","generated_at":"2026-06-24T17:13:34.618402+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Innoviva to acquire La Jolla Pharmaceutical for $6.23/share in cash, ~$149M EV","bullets":["Offer price $6.23/share ($5.95 base + $0.28 from non-core asset sale); 70% premium to 30-day VWAP.","Implied enterprise value approximately $149 million; tender offer expected within ~30 business days.","Adds GIAPREZA (angiotensin II) and XERAVA (eravacycline) to Innoviva's infectious disease portfolio.","Stockholders holding ~40% of La Jolla shares signed support agreement to tender shares.","Transaction unanimously approved by both boards; subject to majority tender and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-025657","json":"https://secwatch.observer/filing/0001140361-22-025657.json","markdown":"https://secwatch.observer/filing/0001140361-22-025657.md","text":"https://secwatch.observer/filing/0001140361-22-025657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/0001140361-22-025657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:13:34.618402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}